Research ArticleOriginal Research

US Primary Care Physicians’ Viewpoints on HPV Vaccination for Adults 27 to 45 Years

Laura P. Hurley, Sean T. O’Leary, Lauri E. Markowitz, Lori A. Crane, Jessica R. Cataldi, Michaela Brtnikova, Brenda L. Beaty, Carol Gorman, Elissa Meites, Megan C. Lindley and Allison Kempe
The Journal of the American Board of Family Medicine January 2021, 34 (1) 162-170; DOI: https://doi.org/10.3122/jabfm.2021.01.200408

References

  1. 1.↵
    1. Satterwhite CL,
    2. Torrone E,
    3. Meites E,
    4. et al
    . Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013;40:187–93.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Centers for Disease Control and Prevention. HPV diseases and cancers. 2019. Available from: https://www.cdc.gov/hpv/parents/cancer.html. Accessed April 15, 2020.
  3. 3.↵
    1. Senkomago V,
    2. Henley SJ,
    3. Thomas CC,
    4. Mix JM,
    5. Markowitz LE,
    6. Saraiya M
    . Human papillomavirus–Attributable Cancers—United States, 2012–2016. MMWR Morb Mortal Wkly Rep 2019;68:724–8. Available from: https://www.cdc.gov/mmwr/volumes/68/wr/mm6833a3.htm. Accessed May 5, 2020.
  4. 4.↵
    American College of Obstetricians and Gynecologists. Committee opinion No. 641: human papillomavirus vaccination. Obstetr Gynecol 2015;126:e38–e43.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Markowitz LE,
    2. Dunne EF,
    3. Saraiya M,
    4. et al
    . Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(Rr-05):1–30.
    OpenUrlPubMed
  6. 6.↵
    Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705–8.
    OpenUrlPubMed
  7. 7.↵
    1. Markowitz LE,
    2. Dunne EF,
    3. Saraiya M,
    4. Lawson HW,
    5. Chesson H,
    6. Unger ER
    . Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1–24.
    OpenUrlPubMed
  8. 8.↵
    1. Castellsague X,
    2. Munoz N,
    3. Pitisuttithum P,
    4. et al
    . End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 2011;105:28–37.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Munoz N,
    2. Manalastas R Jr.,
    3. Pitisuttithum P,
    4. et al
    . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet (London, England) 2009;373:1949–57.
    OpenUrl
  10. 10.↵
    1. Wei L,
    2. Xie X,
    3. Liu J,
    4. et al
    . Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up. Vaccine 2019;37:3617–24.
    OpenUrl
  11. 11.↵
    1. Skinner SR,
    2. Szarewski A,
    3. Romanowski B,
    4. et al
    . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet (London, England) 2014;384:2213–27.
    OpenUrl
  12. 12.↵
    1. Wheeler CM,
    2. Skinner SR,
    3. Del Rosario-Raymundo MR,
    4. et al
    . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. The Lancet Infectious diseases 2016;16:1154–68.
    OpenUrlCrossRef
  13. 13.↵
    1. Giuliano AR,
    2. Isaacs-Soriano K,
    3. Torres BN,
    4. et al
    . Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)—The MAM Study. Vaccine 2015;33:5640–6.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Government of Canada. Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule. 2016. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-human-papillomavirus-vaccine-immunization-schedule.html. Accessed April 17, 2020.
  15. 15.↵
    1. Mazza D,
    2. Petrovic K,
    3. Grech C,
    4. Harris N
    . HPV vaccination in women aged 27 to 45 years: what do general practitioners think? BMC Womens Health 2014;14:91.
    OpenUrl
  16. 16.↵
    1. Lin Y,
    2. Lin Z,
    3. He F,
    4. et al
    . HPV vaccination intent and willingness to pay for 2-,4-, and 9-valent HPV vaccines: a study of adult women aged 27–45 years in China. Vaccine 2020;38:3021–30.
    OpenUrl
  17. 17.↵
    US Department of Health and Human Services FaDA. Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant). Washington, DC: Health and Human Services FaDA; 2018.
  18. 18.↵
    1. Meites E,
    2. Szilagyi PG,
    3. Chesson HW,
    4. Unger ER,
    5. Romero JR,
    6. Markowitz LE
    . Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019;68:698–702.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Centers for Disease Control and Prevention. ACIP Shared Clinical Decision-Making Recommendations. 2020. Available from: https://www.cdc.gov/vaccines/acip/acip-scdm-faqs.html. Accessed May 5, 2020.
  20. 20.↵
    1. Dempsey AF,
    2. Brewer SE,
    3. Pyrzanowski J,
    4. Sevick C,
    5. O’Leary ST
    . Acceptability of human papillomavirus vaccines among women older than 26 years. Vaccine 2015;33:1556–61.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Weiss TW,
    2. Rosenthal SL,
    3. Zimet GD
    . Attitudes toward HPV Vaccination among Women Aged 27 to 45. ISRN Obstet Gynecol 2011;2011:670318.
    OpenUrlPubMed
  22. 22.↵
    1. Nichol KL,
    2. Mac Donald R,
    3. Hauge M
    . Factors associated with influenza and pneumococcal vaccination behavior among high-risk adults. J Gen Intern Med 1996;11:673–7.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.
    1. Nichol KL,
    2. Lofgren RP,
    3. Gapinski J
    . Influenza vaccination. Knowledge, attitudes, and behavior among high-risk outpatients. Arch Intern Med 1992;152:106–10.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.
    1. Armstrong K,
    2. Berlin M,
    3. Schwartz JS,
    4. Propert K,
    5. Ubel PA
    . Barriers to influenza immunization in a low-income urban population. Am J Prevent Med 2001;20:21–5.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Winston CA,
    2. Wortley PM,
    3. Lees KA
    . Factors associated with vaccination of Medicare beneficiaries in five U.S. communities: results from the racial and ethnic adult disparities in immunization initiative survey, 2003. J Am Geriatr Soc 2006;54:303–10.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Rosenthal SL,
    2. Weiss TW,
    3. Zimet GD,
    4. Ma L,
    5. Good MB,
    6. Vichnin MD
    . Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician’s recommendation. Vaccine 2011;29:890–5.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Crane LA,
    2. Daley MF,
    3. Barrow J,
    4. et al
    . Sentinel physician networks as a technique for rapid immunization policy surveys. Eval Health Prof 2008;31:43–64.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Brtnikova M,
    2. Crane LA,
    3. Allison MA,
    4. Hurley LP,
    5. Beaty BL,
    6. Kempe A
    . A method for achieving high response rates in national surveys of U.S. primary care physicians. PLoS One 2018;13:e0202755.
    OpenUrlCrossRef
  29. 29.↵
    1. Dillman DA,
    2. Christian LM
    . Internet, phone, mail, and mixed-mode surveys: the tailored design method. 4th ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2014.
  30. 30.↵
    Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007;196:1438–46.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Garland SM,
    2. Hernandez-Avila M,
    3. Wheeler CM,
    4. et al
    . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928–43.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Mazza D,
    2. Petrovic K,
    3. Chakraborty S
    . HPV vaccination of adult women: an audit of Australian general practitioners. Aust N Z J Obstet Gynaecol 2012;52:528–33.
    OpenUrl
  33. 33.↵
    1. Wimberly YH,
    2. Hogben M,
    3. Moore-Ruffin J,
    4. Moore SE,
    5. Fry-Johnson Y
    . Sexual history-taking among primary care physicians. J Natl Med Assoc 2006;98:1924–9.
    OpenUrlPubMed
  34. 34.↵
    1. Abbo ED,
    2. Zhang Q,
    3. Zelder M,
    4. Huang ES
    . The increasing number of clinical items addressed during the time of adult primary care visits. J Gen Intern Med 2008;23:2058–65.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Ostbye T,
    2. Yarnall KS,
    3. Krause KM,
    4. Pollak KI,
    5. Gradison M,
    6. Michener JL
    . Is there time for management of patients with chronic diseases in primary care? Ann Fam Med 2005;3:209–14.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    Centers for Disease Control and Prevention. Evidence to recommendations for HPV vaccination of adults, ages 27 through 45 years. 2019. Available from: https://www.cdc.gov/vaccines/acip/recs/grade/HPV-adults-etr.html. Accessed April 19, 2020.
  37. 37.↵
    1. Markowitz LE,
    2. Gee J,
    3. Chesson H,
    4. Stokley S
    . Ten years of human papillomavirus vaccination in the United States. Acad Pediatr 2018;18:S3–S10.
    OpenUrlPubMed
  38. 38.↵
    1. Chesson H
    . Overview of Health Economic Models of HPV Vaccination of Mid-Adults. Advisory Committee on Immunization Practices. Published 2019. Available from: https://stacks.cdc.gov/view/cdc/82631/cdc_82631_DS1.pdf. Accessed December 5, 2020.
  39. 39.↵
    1. Laprise JF,
    2. Chesson HW,
    3. Markowitz LE,
    4. et al
    . Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States. Ann Intern Med 2020;172:22–9.
    OpenUrl
  40. 40.↵
    1. Beach MC,
    2. Sugarman J
    . Realizing shared decision-making in practice. JAMA 2019;322:811–2.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords